## Amir Abdollahi

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6231670/publications.pdf

Version: 2024-02-01

81839 82499 5,804 133 39 72 citations g-index h-index papers 138 138 138 8410 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Radioresistance and Transcriptional Reprograming of Invasive Glioblastoma Cells. International Journal of Radiation Oncology Biology Physics, 2022, 112, 499-513.	0.4	10
2	Combined DNA Damage Repair Interference and Ion Beam Therapy: Development, Benchmark, and Clinical Implications of a Mechanistic Biological Model. International Journal of Radiation Oncology Biology Physics, 2022, 112, 802-817.	0.4	6
3	Highâ€Complexity cellular barcoding and clonal tracing reveals stochastic and deterministic parameters of radiation resistance. International Journal of Cancer, 2022, 150, 663-677.	2.3	3
4	Ultra-High Dose Rate (FLASH) Carbon Ion Irradiation:ÂDosimetry and First Cell Experiments. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1012-1022.	0.4	39
5	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. Radiotherapy and Oncology, 2022, 167, 300-307.	0.3	5
6	Deep Learning–based Automatic Lung Segmentation on Multiresolution CT Scans from Healthy and Fibrotic Lungs in Mice. Radiology: Artificial Intelligence, 2022, 4, e210095.	3.0	6
7	Whole Blood Transcriptional Fingerprints of High-Grade Glioma and Longitudinal Tumor Evolution under Carbon Ion Radiotherapy. Cancers, 2022, 14, 684.	1.7	2
8	How can we consider variable RBE and LETd prediction during clinical practice? A pediatric case report at the Normandy Proton Therapy Centre using an independent dose engine. Radiation Oncology, 2022, 17, 23.	1.2	4
9	Neuroprotective Effects of Ultra-High Dose Rate FLASH Bragg Peak Proton Irradiation. International Journal of Radiation Oncology Biology Physics, 2022, 113, 614-623.	0.4	13
10	Biosensor for deconvolution of individual cell fate in response to ion beam irradiation. Cell Reports Methods, 2022, 2, 100169.	1.4	1
11	The Impact of Sub-Millisecond Damage Fixation Kinetics on the In Vitro Sparing Effect at Ultra-High Dose Rate in UNIVERSE. International Journal of Molecular Sciences, 2022, 23, 2954.	1.8	6
12	Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial. Clinical and Translational Radiation Oncology, 2022, 34, 15-22.	0.9	6
13	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. Radiotherapy and Oncology, 2022, 171, 91-100.	0.3	4
14	FLASH with carbon ions: Tumor control, normal tissue sparing, and distal metastasis in a mouse osteosarcoma model. Radiotherapy and Oncology, 2022, 175, 185-190.	0.3	36
15	Biological Dose Optimization for Particle Arc Therapy Using Helium and Carbon Ions. International Journal of Radiation Oncology Biology Physics, 2022, 114, 334-348.	0.4	6
16	Impact of DNA Repair Kinetics and Dose Rate on RBE Predictions in the UNIVERSE. International Journal of Molecular Sciences, 2022, 23, 6268.	1.8	2
17	DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma. Acta Neuropathologica, 2022, 144, 129-142.	3.9	5
18	AAMP is a binding partner of costimulatory human B7-H3. Neuro-Oncology Advances, 2022, 4, .	0.4	4

#	Article	IF	CITATIONS
19	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. Pharmacogenomics Journal, 2021, 21, 37-46.	0.9	6
20	Differential transcriptome response to proton versus X-ray radiation reveals novel candidate targets for combinatorial PT therapy in lymphoma. Radiotherapy and Oncology, 2021, 155, 293-303.	0.3	5
21	modelBuildR: an R package for model building and feature selection with erroneous classifications. PeerJ, 2021, 9, e10849.	0.9	3
22	Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy. Cancers, 2021, 13, 1468.	1.7	24
23	Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy. International Journal of Molecular Sciences, 2021, 22, 2960.	1.8	4
24	KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo. Cancer Letters, 2021, 506, 1-10.	3.2	17
25	Spot-Scanning Hadron Arc (SHArc) Therapy: A Study With Light and Heavy Ions. Advances in Radiation Oncology, 2021, 6, 100661.	0.6	16
26	Deciphering Time-Dependent DNA Damage Complexity, Repair, and Oxygen Tension: A Mechanistic Model for FLASH-Dose-Rate Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 110, 574-586.	0.4	19
27	FLASH Dose Rate Helium Ion Beams: First In Vitro Investigations. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1011-1022.	0.4	34
28	Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality. Molecular Cancer, 2021, 20, 111.	7.9	10
29	Simultaneous targeting of TGF- $\hat{l}^2$ /PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. Cancer Cell, 2021, 39, 1388-1403.e10.	7.7	92
30	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	5.8	237
31	Rapid effective dose calculation for raster-scanning 4He ion therapy with the modified microdosimetric kinetic model (mMKM). Physica Medica, 2021, 81, 273-284.	0.4	10
32	Tumor DNAâ€Methylome derived Epigenetic Fingerprint Identifies HPV â€negative Head and Neck Patients at Risk for Locoregional Recurrence after Postoperative Radiochemotherapy. International Journal of Cancer, 2021, 150, 603.	2.3	2
33	C-MORE: A high-content single-cell morphology recognition methodology for liquid biopsies toward personalized cardiovascular medicine. Cell Reports Medicine, 2021, 2, 100436.	3.3	6
34	Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo. Cancers, 2021, 13, 5898.	1.7	7
35	Evolution of a Paradigm Switch in Diagnosis and Treatment of HPV-Driven Head and Neck Cancer—Striking the Balance Between Toxicity and Cure. Frontiers in Pharmacology, 2021, 12, 753387.	1.6	10
36	Assessment of Normal Tissue Radiosensitivity by Evaluating DNA Damage and Repair Kinetics in Human Brain Organoids. International Journal of Molecular Sciences, 2021, 22, 13195.	1.8	3

3

#	Article	IF	Citations
37	Development and Validation of Single Field Multi-Ion Particle Therapy Treatments. International Journal of Radiation Oncology Biology Physics, 2020, 106, 194-205.	0.4	43
38	Isolation of timeâ€dependent DNA damage induced by energetic carbon ions and their fragments using fluorescent nuclear track detectors. Medical Physics, 2020, 47, 272-281.	1.6	14
39	An R package for an integrated evaluation of statistical approaches to cancer incidence projection. BMC Medical Research Methodology, 2020, 20, 257.	1.4	41
40	FRoG: An independent dose and LET <sub>d</sub> prediction tool for proton therapy at ProBeam® facilities. Medical Physics, 2020, 47, 5274-5286.	1.6	14
41	A scalable CRISPR/Cas9-based fluorescent reporter assay to study DNA double-strand break repair choice. Nature Communications, 2020, 11, 4077.	5.8	33
42	Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma. International Journal of Molecular Sciences, 2020, 21, 7801.	1.8	8
43	Mapping the Relative Biological Effectiveness of Proton, Helium and Carbon Ions with High-Throughput Techniques. Cancers, 2020, 12, 3658.	1.7	13
44	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. BMC Cancer, 2020, 20, 557.	1.1	29
45	Assessment of RBE-Weighted Dose Models for Carbon Ion Therapy Toward Modernization of Clinical Practice at HIT: InÂVitro, inÂVivo, and in Patients. International Journal of Radiation Oncology Biology Physics, 2020, 108, 779-791.	0.4	39
46	Study of the intracellular nanoparticle-based radiosensitization mechanisms in F98 glioma cells treated with charged particle therapy through synchrotron-based infrared microspectroscopy. Analyst, The, 2020, 145, 2345-2356.	1.7	9
47	Personalized Assessment of Normal Tissue Radiosensitivity via Transcriptome Response to Photon, Proton and Carbon Irradiation in Patient-Derived Human Intestinal Organoids. Cancers, 2020, 12, 469.	1.7	9
48	Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival. Clinical Cancer Research, 2020, 26, 2231-2243.	3.2	21
49	Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature. Cancer Immunology, Immunotherapy, 2020, 69, 1823-1832.	2.0	19
50	Comparison of GeneChip, nCounter, and Real-Time PCR–Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. Journal of Molecular Diagnostics, 2020, 22, 801-810.	1.2	10
51	Carbon ion dosimetry on a fluorescent nuclear track detector using widefield microscopy. Physics in Medicine and Biology, 2020, 65, 21NT02.	1.6	5
52	Biophysical modeling and experimental validation of relative biological effectiveness (RBE) for 4He ion beam therapy. Radiation Oncology, 2019, 14, 123.	1.2	37
53	Dosimetric validation of Monte Carlo and analytical dose engines with raster-scanning 1H, 4He, 12C, and 16O ion-beams using an anthropomorphic phantom. Physica Medica, 2019, 64, 123-131.	0.4	18
54	The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. Clinical Cancer Research, 2019, 25, 3152-3163.	3.2	53

#	Article	lF	CITATIONS
55	Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma. Cancers, 2019, 11, 122.	1.7	25
56	Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentreÂretrospective study of the German Cancer Consortium Radiation Oncology Group. European Journal of Cancer, 2019, 116, 67-76.	1.3	58
57	Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer. International Journal of Cancer, 2019, 145, 3299-3310.	2.3	34
58	Impact of post-surgical freezing delay on brain tumor metabolomics. Metabolomics, 2019, 15, 78.	1.4	9
59	Identification of KIF11 As a Novel Target in Meningioma. Cancers, 2019, 11, 545.	1.7	31
60	P11.07 LAPTM5 functions as a tumor suppressor via CD40 - NFêB pathway inhibition and represents a potential biomarker for temozolomide sensitivity in CD40 proficient glioblastoma. Neuro-Oncology, 2019, 21, iii43-iii43.	0.6	0
61	Modeling the Effect of Hypoxia and DNA Repair Inhibition on Cell Survival After Photon Irradiation. International Journal of Molecular Sciences, 2019, 20, 6054.	1.8	12
62	Large scale <i>in vivo</i> microâ€RNA loss of function screen identified miRâ€29a, miRâ€100 and miRâ€155 as modulators of radioresistance and tumorâ€stroma communication. International Journal of Cancer, 2019, 144, 2774-2781.	2.3	8
63	Determining RBE for development of lung fibrosis induced by fractionated irradiation with carbon ions utilizing fibrosis index and high-LET BED model. Clinical and Translational Radiation Oncology, 2019, 14, 25-32.	0.9	7
64	Synthetic phosphopeptides: From spike-in standards to affinity tools for protein-protein interaction studies. Analytical Biochemistry, 2019, 568, 73-77.	1.1	0
65	Modeling and multiscale characterization of the quantitative imaging based fibrosis index reveals pathophysiological, transcriptome and proteomic correlates of lung fibrosis induced by fractionated irradiation. International Journal of Cancer, 2019, 144, 3160-3173.	2.3	13
66	Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche. JCI Insight, $2019,4,.$	2.3	63
67	Glioblastoma evolution pattern under surgery and radio(chemo)therapy (RCHT) to identify novel methylome based glioma subtypes Journal of Clinical Oncology, 2019, 37, 2012-2012.	0.8	3
68	A solidâ€phase transfection platform for arrayed CRISPR screens. Molecular Systems Biology, 2019, 15, e8983.	3.2	8
69	Clonal tumor evolution under induction chemotherapy and concurrent radiochemotherapy (RCHT) in patients with resectable stage IIIA (N2) and selected IIIb non-small cell lung cancer (NSCLC): Molecular analysis of the ESPATUE randomized phase III trial Journal of Clinical Oncology, 2019, 37, 8543-8543.	0.8	0
70	Efficacy of re-irradiation with carbon ions (RiCi) in patients with recurrent high-grade glioma (rHGG) compared to the standard re-irradiation with photons (RiP): The reference multicenter cohort of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) Journal of Clinical Oncology, 2019, 37, 2057-2057.	0.8	2
71	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. Radiotherapy and Oncology, 2018, 127, 27-35.	0.3	17
72	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. Radiotherapy and Oncology, 2018, 126, 125-131.	0.3	24

#	Article	IF	CITATIONS
73	Feasibility and robustness of dynamic 18F-FET PET based tracer kinetic models applied to patients with recurrent high-grade glioma prior to carbon ion irradiation. Scientific Reports, 2018, 8, 14760.	1.6	15
74	Cellular Barcoding Identifies Clonal Substitution as a Hallmark of Local Recurrence in a Surgical Model of Head and Neck Squamous Cell Carcinoma. Cell Reports, 2018, 25, 2208-2222.e7.	2.9	30
75	Fast robust dose calculation on GPU for high-precision 1H, 4He, 12C and 16O ion therapy: the FRoG platform. Scientific Reports, 2018, 8, 14829.	1.6	41
76	Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC. Radiation Oncology, 2018, 13, 1.	1.2	73
77	Impact of 18F-FET PET on Target Volume Definition and Tumor Progression of Recurrent High Grade Glioma Treated with Carbon-Ion Radiotherapy. Scientific Reports, 2018, 8, 7201.	1.6	33
78	Combined external beam radiotherapy with carbon ions and tumor targeting endoradiotherapy. Oncotarget, 2018, 9, 29985-30004.	0.8	11
79	Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines. Cancer Biology and Therapy, 2017, 18, 400-406.	1.5	12
80	Application of fluorescent nuclear track detectors for cellular dosimetry. Physics in Medicine and Biology, 2017, 62, 2719-2740.	1.6	14
81	STED microscopy visualizes energy deposition of single ions in a solid-state detector beyond diffraction limit. Physics in Medicine and Biology, 2017, 62, N180-N190.	1.6	10
82	Deciphering the Acute Cellular Phosphoproteome Response to Irradiation with X-rays, Protons and Carbon Ions. Molecular and Cellular Proteomics, 2017, 16, 855-872.	2.5	27
83	Optimization of Monte Carlo particle transport parameters and validation of a novel high throughput experimental setup to measure the biological effects of particle beams. Medical Physics, 2017, 44, 6061-6073.	1.6	20
84	Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation. Radiation Oncology, 2017, 12, 208.	1.2	75
85	Quantitative assessment of radiation dose and fractionation effects on normal tissue by utilizing a novel lung fibrosis index model. Radiation Oncology, 2017, 12, 172.	1.2	16
86	Next generation multi-scale biophysical characterization of high precision cancer particle radiotherapy using clinical proton, helium-, carbon- and oxygen ion beams. Oncotarget, 2016, 7, 56676-56689.	0.8	72
87	<i>LOC283731</i> promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wildâ€type glioblastoma patients. International Journal of Cancer, 2016, 139, 424-432.	2.3	18
88	Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone. BMC Medicine, 2016, 14, 170.	2.3	31
89	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).  Radiotherapy and Oncology, 2016, 121, 364-373.	0.3	130
90	Registration procedure for spatial correlation of physical energy deposition of particle irradiation and cellular response utilizing cell-fluorescent ion track hybrid detectors. Physics in Medicine and Biology, 2016, 61, N441-N460.	1.6	11

#	Article	IF	CITATIONS
91	K-Ras and cyclooxygenase-2 coactivation augments intraductal papillary mucinous neoplasm and Notch1 mimicking human pancreas lesions. Scientific Reports, 2016, 6, 29455.	1.6	6
92	Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3DÂconformal radiotherapy in anaplastic astrocytoma and glioblastoma. Strahlentherapie Und Onkologie, 2016, 192, 770-779.	1.0	39
93	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(â^') HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clinical Cancer Research, 2016, 22, 2639-2649.	3.2	127
94	Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. Radiotherapy and Oncology, 2016, 118, 350-358.	0.3	62
95	Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation. European Journal of Cancer, 2016, 57, 78-86.	1.3	62
96	Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling. Gastroenterology, 2016, 150, 513-525.e10.	0.6	78
97	Radiosensitivity of Patient-Derived Glioma Stem Cell 3-Dimensional Cultures to Photon, Proton, and Carbon Irradiation. International Journal of Radiation Oncology Biology Physics, 2016, 95, 112-119.	0.4	46
98	Genetic changes of non-small cell lung cancer under neoadjuvant therapy. Oncotarget, 2016, 7, 29761-29769.	0.8	16
99	Correlation of Particle Traversals with Clonogenic Survival Using Cell-Fluorescent Ion Track Hybrid Detector. Frontiers in Oncology, 2015, 5, 275.	1.3	9
100	Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta Neuropathologica, 2015, 130, 419-434.	3.9	74
101	Stem Cell-Specific Mechanisms Ensure Genomic Fidelity within HSCs and upon Aging of HSCs. Cell Reports, 2015, 13, 2412-2424.	2.9	48
102	Synergistic effects of crizotinib and radiotherapy in experimental EML4–ALK fusion positive lung cancer. Radiotherapy and Oncology, 2015, 114, 173-181.	0.3	43
103	For the Next Trick: New Discoveries in Radiobiology Applied to Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e95-e99.	1.8	22
104	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2014, 113, 317-323.	0.3	141
105	Multimodal Therapies for Pancreatic Cancer. , 2014, , 39-73.		0
106	Deciphering the Systems Biology of mTOR Inhibition by Integrative Transcriptome Analysis. Current Pharmaceutical Design, 2014, 20, 88-100.	0.9	15
107	Engineering cell-fluorescent ion track hybrid detectors. Radiation Oncology, 2013, 8, 141.	1.2	24
108	Subcellular Spatial Correlation of Particle Traversal and Biological Response in Clinical Ion Beams. International Journal of Radiation Oncology Biology Physics, 2013, 87, 1141-1147.	0.4	28

7

#	Article	IF	Citations
109	Systems Biology of Pancreatic Cancer: The Role of Tumor-Microenvironment Communication in Development, Progression and Therapy Resistance. , 2012, , 135-164.		0
110	Identification of stable endogenous control genes for transcriptional profiling of photon, proton and carbon-ion irradiated cells. Radiation Oncology, 2012, 7, 70.	1.2	19
111	Consensus Micro RNAs Governing the Switch of Dormant Tumors to the Fast-Growing Angiogenic Phenotype. PLoS ONE, 2012, 7, e44001.	1.1	53
112	Gene Expression Signatures in the Peripheral Blood After Radiosurgery of Human Cerebral Arteriovenous Malformations. Strahlentherapie Und Onkologie, 2010, 186, 91-98.	1.0	7
113	Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. FASEB Journal, 2010, 24, 1411-1418.	0.2	96
114	Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resistance Updates, 2010, 13, 16-28.	6.5	208
115	MicroRNA expression after ionizing radiation in human endothelial cells. Radiation Oncology, 2010, 5, 25.	1.2	130
116	Whole Blood Transcriptomics in Cardiac Surgery Identifies a Gene Regulatory Network Connecting Ischemia Reperfusion with Systemic Inflammation. PLoS ONE, 2010, 5, e13658.	1.1	33
117	Transcriptional Switch of Dormant Tumors to Fast-Growing Angiogenic Phenotype. Cancer Research, 2009, 69, 836-844.	0.4	223
118	Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Molecular Cancer Therapeutics, 2009, 8, 1494-1504.	1.9	91
119	TableButler – a Windows based tool for processing large data tables generated with high-throughput methods. BMC Bioinformatics, 2009, 10, 235.	1.2	6
120	Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood, 2009, 114, 1987-1998.	0.6	39
121	Combination of Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor Inhibition Markedly Improves Radiation Tumor Therapy. Clinical Cancer Research, 2008, 14, 2210-2219.	3.2	125
122	Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12890-12895.	3.3	198
123	Randomized phase II $\hat{a} \in \text{``}$ study evaluating EGFR targeting therapy with Cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer $\hat{a} \in \text{``}$ PARC: study protocol [ISRCTN56652283]. BMC Cancer, 2005, 5, 131.	1.1	61
124	Trimodal Cancer Treatment: Beneficial Effects of Combined Antiangiogenesis, Radiation, and Chemotherapy. Cancer Research, 2005, 65, 3643-3655.	0.4	171
125	Inhibition of $\hat{l}\pm v\hat{l}^2$ 3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy. Clinical Cancer Research, 2005, 11, 6270-6279.	3.2	210
126	Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. Journal of Experimental Medicine, 2005, 201, 925-935.	4.2	345

#	Article	IF	CITATIONS
127	Endostatin: The logic of antiangiogenic therapy. Drug Resistance Updates, 2005, 8, 59-74.	6.5	100
128	Apoptosis signals in lymphoblasts induced by focused ultrasound. FASEB Journal, 2004, 18, 1413-1414.	0.2	58
129	Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1220-1232.	0.4	58
130	Endostatin's Antiangiogenic Signaling Network. Molecular Cell, 2004, 13, 649-663.	4.5	375
131	Computed Tomography Monitoring of Radiation-Induced Lung Fibrosis in Mice. Investigative Radiology, 2004, 39, 600-609.	3.5	64
132	SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Research, 2003, 63, 3755-63.	0.4	124
133	Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Research, 2003, 63, 8890-8.	0.4	125